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Abstract
A key component of any health system is the capacity to accurately diagnose individuals. One of the six building
blocks of a health system as defined by the World Health Organization (WHO) includes diagnostic tools. The WHO’s
Noncommunicable Disease Global Action Plan includes addressing the lack of diagnostics for noncommunicable
diseases, through multi-stakeholder collaborations to develop new technologies that are affordable, safe, effective
and quality controlled, and improving laboratory and diagnostic capacity and human resources. Many challenges
exist beyond price and availability for the current tools included in the Package of Essential Noncommunicable
Disease Interventions (PEN) for cardiovascular disease, diabetes and chronic respiratory diseases. These include
temperature stability, adaptability to various settings (e.g. at high altitude), need for training in order to perform and
interpret the test, the need for maintenance and calibration, and for Blood Glucose Meters non-compatible meters
and test strips. To date the issues surrounding access to diagnostic and monitoring tools for noncommunicable
diseases have not been addressed in much detail. The aim of this Commentary is to present the current landscape
and challenges with regards to guidance from the WHO on diagnostic tools using the WHO REASSURED criteria,
which define a set of key characteristics for diagnostic tests and tools. These criteria have been used for
communicable diseases, but so far have not been used for noncommunicable diseases. Diagnostic tools have
played an important role in addressing many communicable diseases, such as HIV, TB and neglected tropical
diseases. Clearly more attention with regards to diagnostics for noncommunicable diseases as a key component of
the health system is needed.
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Introduction
A key component of any health system is the capacity to
diagnose individuals with a given condition. One of the
six building blocks of a health system as defined by the
World Health Organization (WHO) includes diagnostic
tools. Specifically, for noncommunicable diseases (NCD),
the WHO’s Noncommunicable Disease Global Action
Plan (NCD GAP) includes addressing the lack of diag-
nostics through multi-stakeholder collaborations to de-
velop new technologies that are affordable, safe, effective
and quality controlled, and improving laboratory and
diagnostic capacity and human resources [1]. Specific-
ally, the NCD GAP includes a target of: “an 80 % avail-
ability of the affordable basic technologies and essential
medicines, including generics, required to treat major
noncommunicable diseases in both public and private fa-
cilities” [1], which should be ensured.
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In 2018, the WHO published the first edition of the
Model Essential Diagnostics List (EDL) which was up-
dated in 2019 [2]. The EDL, similar to the WHO Model
List of Essential Medicines (EML), was aimed at ensur-
ing essential diagnostics are available for the achieve-
ment of Universal Health Coverage (UHC). As with the
EML, the EDL aims to serve as a guiding document for
countries in ensuring availability of diagnostic tools. The
EDL comprises 122 test categories including general and
disease-specific tests. In the case of diabetes, tests in-
cluded are those for glucose (urine dipsticks, gluc-
ometers and clinical chemistry and immunoassays),
glycated haemoglogin (small analysers and clinical
chemistry and immunoassays), and diabetic ketoacidosis
(Electro-analytical method Handheld analyser).
Other guidance produced by the WHO, the Package
of Essential Noncommunicable Disease Interventions
(PEN), focuses on primary healthcare (PHC) [3] and in-
cludes in its “package” a set of diagnostic tools for the
diagnosis and management of cardiovascular disease
(CVD), diabetes and asthma, but not cancer. Within the
PEN package, breast and cervical cancer are included,
but with a view of “assessment and referral” of individ-
uals [3]. In addition, it is important to note that WHO
guidance in the area of diagnostic and monitoring fo-
cuses on facility-based tools and does not consider tools
for individual’s self management of their condition.
However, both at facilities and for individuals, NCD
diagnostic and monitoring tools have been found to be
unavailable within health systems and/or unaffordable to
individuals who have to pay for tests within the health
system or purchase these tools for their self-monitoring.
For example, for diabetes it was found that in Mali,
Mozambique and Zambia urine test strips and blood
glucose monitors (BGMs) were available in 54 % and
13 %, and 18 % and 21 %, and 61 % and 49 % of health fa-
cilities, respectively [4]. Costs of facility based testing, as-
suming one monthly blood glucose test, ranged from
free in Nicaragua to US$ 27 per annum in Mali. For the
use of personal meters, only wealthy individuals in low-
and middle-income countries (LMIC) [4] and children
benefitting from donation programs [5] had access to
these devices. Similar cases of inequity may occur in
other LMICs. To date, many studies have looked at the
availability or affordability of these tools [4, 6, 7], but not
necessarily if they are “technically” adapted to LMIC set-
tings. This Commentary will present the current land-
scape and challenges with regards to diagnostic and
monitoring tools for NCDs included in WHO’s guidance
for PHC using the REASSURED criteria [8] in order to
understand barriers to access to diagnostic tools, the
complexities of these need to be assessed.
The REASSURED Criteria
The REASSURED criteria (Table 1) are a set of charac-
teristics developed for assessing diagnostic tools for
communicable diseases (CD) and have been used for
over a decade with the recent addition of three new at-
tributes: real time connectivity, ease of specimen collec-
tion, and environmentally friendly [8] which allow for
Table 1 REASSURED criteria for diagnostic tests included in WHO PEN Package
This table presents each of the REASSURED criteria using a traffic light system with red: not at all; orange to a certain extent; and green yes
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the key characteristics of diagnostic tools, specifically for
LMICs, to be assessed. These include [8]:
– Real time connectivity: Tests are connected and/or a
reader or mobile phone is used to power the
reaction and/or read test results to provide required
data to clinicians and users.
– Ease of specimen collection: Tests should be
designed for use with non-invasive specimens.
– Affordable: Tests are affordable to end-users and the
health system.
– Sensitive: Avoid false negatives.
– Specific: Avoid false positives.
– User-friendly: Procedure of testing is simple — can
be performed in a few steps, requiring minimum
training.
– Rapid and Robust: Results are available to ensure
treatment of patient at first visit (typically, this
means results within 15 min to 2 h) and the tests
can survive the supply chain without requiring
additional transport and storage conditions such as
refrigeration.
– Equipment free and environmentally friendly: Ideally
the test does not require any special equipment or
can be operated in very simple devices that use solar
or battery power. Completed tests are easy to
dispose and manufactured from recyclable materials.
– Deliverable to end-users: Accessible to those who
need the tests the most.
Applying the REASSURED Criteria to
Noncommunicable disease diagnostic and
monitoring tools
In order to present an overall view of the barriers to
NCD diagnostics the REASSURED criteria were applied
to tools used to diagnose and manage the NCDs in-
cluded as part of the PEN package, namely CVD, dia-
betes and asthma based on a review of the literature.
For blood pressure different means of measurement
exist, such as using a mercury or aneroid sphygmoman-
ometer or an automated blood pressure monitor [9].
Mercury sphygmomanometers are seen as the gold
standard technique for measuring blood pressure, with
high sensitivity and specificity compared to aneroid and
automatic monitors. However, this tool requires the
most training of personnel. Overall, availability and af-
fordability of blood pressure measuring devices are vari-
able and all tools require additional equipment (i.e.
either a stethoscope, batteries) and calibration [9–11].
All tools face similar issues with regards to robustness of
the test.
BGMs are essential for the diagnosis and monitoring
of diabetes. Compared to gold standard laboratory based
tests, BGMs are not specific or sensitive [12].
Affordability and availability of BGM as a diagnostic and
monitoring tool in health facilities as well as a monitor-
ing tool for individuals are challenges [4]. Part of this
cost is also due to the need for single-use strips that are
only compatible with a given brand of meter as well as
other consumables, such as lancets and batteries. Issues
of robustness also exist as these tools can be affected by
temperature and humidity [13]. It should also be noted
that meters change frequently with an impact on which
strips can be used.
Forced expiratory volume in 1s/forced vital capacity
ratio (FEV1/FVC ratio: Tiffeneau-Pinelli index) is used in
the diagnosis and management of asthma and chronic
obstructive pulmonary disease (COPD) using a spirom-
eter [14]. The peak flow rate can also be used for the
diagnosis and follow-up of people with COPD and
asthma. For the measurement of the peak expiratory
flow (PEF), a peak flow meter can be used. Both spirom-
eters and peak flow meters are used to determine lung
capacity using different calculations. However, measure-
ment error is higher for PEF [14]. Peak flow meters in
general have poor sensitivity and specificity in diagnos-
ing asthma and COPD and are mainly used for monitor-
ing these conditions. Cost, availability and the need for
consumables are the main barriers of access to spirom-
etry [15]. In addition, health professional training can be
seen as a secondary barrier as well as an absence of
guidelines for both tests.
Details of the REASSURED criteria for all these tests
are included in Table 1.
Diagnostic tools for NCDs: more guidance is
needed
Clearly more attention with regards to diagnostics as a
key component of the health system is needed. Despite
the existance of global guidance, the issue of access to
diagnostics does not feature prominently on the global
NCD agenda, in comparison for example to access to
medicines. The EDL and PEN Package provide a list of
tools that should be available, and the NCD GAP a tar-
get to be achieved. However, the target included in the
NCD GAP focuses on availability and affordability and
our review of the tools using the REASSURED criteria
presents a wide range of challenges beyond price and
availability, such as temperature stability, adaptability to
various settings (e.g. at high altitude), need for training
in order to perform and interpret the test, the need for
maintenance and calibration, and for BGMs non-
compatible meters and test strips. When used as self-
monitoring tools by the individual at home they require
training and skills to be delivered by capable health pro-
fessionals. For NCDs, the EDL only includes tests where
a sample needs to be taken and does not include blood
pressure measuring devices or spirometers, which are
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also part of the equipment needed to diagnose and
monitor patients.
Conclusions
Access to diagnostic tests for NCDs does not necessarily
result in their wide uptake and effective use and better
outcomes for NCD management, and needs to be inte-
grated in a health system wide response, including an
understanding of key barriers that prevent sustainable
access to health facilities, medicines, trained profes-
sionals and information, education and empowerment
for people with the given conditions. Diagnostic tools
have played an important role in addressing many CDs,
such as HIV, TB and neglected tropical diseases. For
NCDs a whole portfolio of diagnostic and monitoring
tools are required throughout the continuum of care.
These include tools for the initial diagnosis of the indi-
vidual. For most NCDs the diagnostic test, blood pres-
sure or blood glucose, needs to be assessed with a view
of the overall risk of the individual, versus a “yes or no”
diagnosis. For the ongoing follow-up and management
of the individual this overall risk needs to be monitored
as well as the need to ensure the availability of tests
within facilities. In addition, for diabetes and hyperten-
sion part of the management for the individual may be
done at home and includes the use of different self-
monitoring tools. Then at regular intervals additional
biological or physiological factors may need to be mea-
sured to assess disease progression. Finally, specialised
tests carried out less frequently to detect complications
also form part of the overall toolbox needed. The bar-
riers identified need to be addressed to ensure better
availability, affordability and uptake of adapted tools for
LMIC contexts. Innovation in diagnostics is an oppor-
tunity to address barriers to access and adapt current
tools to LMIC contexts. However, from the very outset,
innovation should consider the REASSURED criteria to
ensure that the tools developed meet the needs of
LMICs and assist in addressing the global NCD
challenge.
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